There Was Fresh Hope for Catching Lung Cancer Early

Scientists have found 14 proteins in the blood that can predict whether a person will develop lung cancer more than five years before any diagnosis.

That is the kind of finding that could rewrite how doctors approach one of the world’s most lethal diseases.

The research, published in the journal Cell, was led by researchers at University College London (UCL) and the Francis Crick Institute, two of the United Kingdom’s most respected scientific institutions.

Using machine learning, the team analysed blood plasma data from more than 48,000 people enrolled in the UK Biobank, a large long-term health study.

They cross-referenced those samples with cancer registry records to identify participants who later went on to develop lung cancer.

What emerged was a 14-protein signature that, when elevated in the blood, signals a significantly higher risk of the disease taking hold.

The proteins do not come from the tumour itself.

They reflect something happening in the lungs long before cancer appears, a state of chronic inflammation that quietly prepares the ground for the disease to grow.

“We’ve shown that the signature reflects an altered inflammatory lung environment before cancer takes hold,” said Tej Pandya, a Clinical PhD Student at UCL and visiting scientist at the Crick.

That detail changes everything about how we think of lung cancer risk.

How the Study Was Conducted

The research team started with a simple but ambitious question: could a blood test reveal who is heading toward lung cancer before symptoms appear and before a tumour is visible on a scan?

To answer it, they turned to the UK Biobank, one of the world’s largest collections of biological and health data.

They applied machine learning algorithms to analyse thousands of proteins measured in the blood plasma of more than 48,000 participants.

By comparing protein levels in people who later developed lung cancer against those who did not, the algorithm identified patterns invisible to the human eye.

The result was a panel of 14 key proteins that, when considered alongside a person’s age, smoking history, and history of lung disease, consistently predicted future lung cancer diagnoses.

Crucially, the team did not stop there.

They validated the findings across eight independent datasets drawn from research groups on five continents, involving more than 80 collaborators worldwide.

That level of external validation is rare and important.

It means the protein signature does not just work in the UK population, it holds up across different ethnicities, geographies, and health systems.

The study also used mouse models to investigate the biology behind the signature, confirming that the proteins reflect a state of pre-cancerous lung inflammation rather than the tumour itself.

Findings From the Study

The headline finding is striking enough on its own: 14 proteins in the blood can predict lung cancer more than five years before diagnosis.

But the details behind that finding are what make the science genuinely exciting.

The protein signature does not reflect the tumour.

It reflects the environment in the lungs that allows a tumour to eventually develop.

Professor Charles Swanton of UCL, one of the lead investigators, described it this way: the signature suggests that some common age-related diseases share a pre-symptomatic state of chronic inflammation that precedes the disease itself.

Think of it like a weather forecast, not for rain, but for a fire.

The protein signature is detecting the dry conditions long before a spark takes hold.

The researchers also identified specific biological targets within the signature, particularly anti-IL-1β pathways, a part of the immune system involved in regulating inflammation.

This matters because drugs that target IL-1β already exist and have been tested in other conditions.

The implication is that some people identified through this blood test may one day be offered preventive drug treatment to cool the inflammatory environment in their lungs before cancer can develop.

Professor Swanton drew a comparison to statins, the cholesterol-lowering drugs that have transformed the prevention of heart disease.

“Drugs like statins have transformed the prevention of cardiovascular disease,” he said.

“Finding a signal for an inflammatory state in the lungs has given us insight into this window of opportunity, when preventative treatment could work best.”

The study did not test any drugs.

But it opened a clear biological roadmap toward doing exactly that.

But Here Is What Most People Get Wrong About Lung Cancer Risk

When most people think of lung cancer, they think of one thing: smoking.

And for decades, that has been the foundation of every screening programme and prevention campaign.

Doctors screen older adults who have smoked heavily.

Everyone else is essentially told they are not at risk.

That assumption is increasingly out of date.

About 20% of lung cancer cases now occur in people who have never smoked, according to researchers at Henry Ford Health in Detroit, who studied more than 2,200 lung cancer cases diagnosed over nearly a decade.

That is not a rounding error.

That is one in five people with lung cancer who had no history of tobacco use.

A major study published in Nature in July 2025, led by researchers at the National Cancer Institute and the University of California San Diego, found that fine-particle air pollution is strongly linked to lung cancer mutations in non-smokers.

People with high lifetime exposure to PM2.5 particles, the tiny pollutants produced by vehicles, industry, and burning fossil fuels, were 1.6 times more likely to carry a specific tumour-suppressing gene mutation associated with cancer.

A separate analysis published in The Lancet Respiratory Medicine found that adenocarcinoma, the lung cancer subtype most common in non-smokers, now accounts for more than 45% of cases in men and nearly 60% in women worldwide.

The biggest driver?

Air pollution, particularly in heavily urbanised regions of East Asia.

This is the part most people have not fully absorbed yet.

Lung cancer is no longer primarily a disease of smokers in wealthy countries.

It is becoming a disease of anyone who breathes polluted air, and that means billions of people around the world are carrying a risk that current screening programmes were never designed to catch.

The UCL and Francis Crick study was designed with exactly this gap in mind.

The current system, which limits lung cancer screening to older adults with a heavy smoking history, is already missing a huge portion of people who are at genuine risk.

A blood test that reads biological signals of inflammation, not just lifestyle history, has the potential to find those people.

How the Study Applies to Real Life

The most immediate question anyone reading this is likely to ask is: when can I get this test?

The honest answer is that it is not available yet as a clinical tool.

The research is at the stage of proof of concept, which is the critical first stage.

Before the test can be offered to patients, researchers need to establish exactly how and when it should be used, who should receive it, how often, and what should happen when someone tests positive.

That work is underway, but it takes time.

Still, the implications for real life are already clear.

Early diagnosis saves lives.

According to the American Lung Association’s 2025 State of Lung Cancer report, when lung cancer is caught at an early stage, the five-year survival rate is 65%.

When it is caught late, that figure drops to just 10%.

Right now, only about 28% of lung cancer cases in the United States are diagnosed at an early stage.

More than 43% are caught only after the cancer has already spread.

Those numbers tell the story of why this research matters so urgently.

Most people who die from lung cancer do not die because treatment does not exist.

They die because the cancer was not found in time.

A blood test that can identify risk five or more years before diagnosis fundamentally changes that equation.

It creates a window of opportunity, as Professor Swanton described it, in which doctors can watch more carefully, scan more frequently, or potentially intervene with drugs that reduce inflammation before a tumour forms.

The Bigger Picture: Inflammation as a Root Cause

One of the most thought-provoking ideas embedded in this research is not just about lung cancer.

It is about how the human body ages, and what goes wrong during that process.

Professor Swanton described the protein signature as part of a “relatively new idea” in cancer biology: that some of the most common diseases of ageing share a common pre-symptomatic state of inflammation long before symptoms appear.

This is sometimes called inflammaging, the gradual, low-grade inflammation that accumulates as we grow older, driven by decades of environmental exposure, cell damage, and immune system wear.

Cancer is not the only disease linked to this process.

Heart disease, type 2 diabetes, Alzheimer’s, and chronic lung conditions all share inflammation as a contributing factor.

What makes the lung cancer protein signature significant beyond its immediate application is that it could point toward a new way of thinking about prevention across multiple diseases.

If we can detect a pre-cancerous inflammatory state before it tips into disease, we may eventually be able to intervene at that earlier, more treatable moment.

That is a profound shift in medical thinking, from treating illness to preventing the conditions that allow illness to develop.

Building on earlier research at the Crick and UCL showing that air pollution wakes up dormant cells that carry cancer-causing mutations, this new study fits into a larger picture of how environmental exposures interact with our biology over time.

A person does not develop lung cancer overnight.

It is a slow accumulation of inflammatory damage, genetic change, and cellular dysfunction over years or decades.

The 14-protein blood signature may be the first reliable way to read those early warning signs before they become irreversible.

What Happens Next

The researchers are clear that more work is needed before this test reaches patients.

The protein signature needs to be studied in clinical trial settings to understand its performance in a real-world screening context.

Scientists also want to understand more precisely which of the 14 proteins matter most, and whether certain combinations of proteins predict specific subtypes of lung cancer or specific risk timelines.

There is also the question of who should be screened.

The current model relies on age and smoking history to identify candidates for lung cancer screening with low-dose CT scans.

The protein blood test, if validated further, could eventually complement that approach by identifying high-risk individuals regardless of whether they have ever smoked, addressing the growing population of non-smokers with lung cancer driven by air pollution and other environmental factors.

Drug trials targeting the IL-1β inflammatory pathway are also likely to follow.

Researchers already have a biological mechanism and a way to identify who carries the relevant inflammatory signature.

That is the kind of foundation needed to design a meaningful prevention trial.

A New Chapter for Cancer Prevention

Lung cancer kills more people than any other cancer.

It does so largely because it is almost always found too late.

The work done by UCL and the Francis Crick Institute represents a meaningful step toward changing that, not by finding better treatments for late-stage disease, but by finding the people at risk before the disease takes hold.

The idea that a routine blood test might one day tell someone they are on a path toward lung cancer, and that there are steps to take to interrupt that path, is not science fiction.

It is where the science is now pointing.

The 14-protein signature identified in this research is not a final answer.

But it is a serious, rigorously validated signal, tested across continents, confirmed in animal models, and published in one of the world’s most respected scientific journals.

For the millions of people who might be at risk but would never be caught by today’s screening criteria, especially those who have never smoked but live in polluted cities or carry the quiet biological markers of a lung environment under stress, that matters enormously.

The next step is not just for scientists.

It is a conversation worth having with your doctor, especially if you live in a heavily polluted area, have a family history of lung disease, or fall outside the narrow bracket of who currently qualifies for lung cancer screening.

The science of prevention is catching up.

And for the first time in a long time, that feels like a genuinely hopeful thing.